Coya Therapeutics, Inc.
COYA
$6.73
$0.233.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -36.56% | 12,795.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -36.56% | 12,795.00% | |||
| Cost of Revenue | -29.75% | 169.13% | |||
| Gross Profit | 29.39% | -156.07% | |||
| SG&A Expenses | 7.16% | 26.94% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.10% | 94.38% | |||
| Operating Income | 16.44% | -88.15% | |||
| Income Before Tax | 16.58% | -100.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.58% | -150.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.58% | -150.59% | |||
| EBIT | 16.44% | -88.15% | |||
| EBITDA | 16.46% | -88.29% | |||
| EPS Basic | 16.61% | -145.09% | |||
| Normalized Basic EPS | 16.59% | -96.62% | |||
| EPS Diluted | 16.61% | -145.09% | |||
| Normalized Diluted EPS | 16.59% | -96.62% | |||
| Average Basic Shares Outstanding | 0.03% | 2.22% | |||
| Average Diluted Shares Outstanding | 0.03% | 2.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||